Lasse Kjær

3.1k total citations
125 papers, 2.0k citations indexed

About

Lasse Kjær is a scholar working on Genetics, Hematology and Rheumatology. According to data from OpenAlex, Lasse Kjær has authored 125 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 80 papers in Genetics, 47 papers in Hematology and 37 papers in Rheumatology. Recurrent topics in Lasse Kjær's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (77 papers), Eosinophilic Disorders and Syndromes (36 papers) and Chronic Myeloid Leukemia Treatments (30 papers). Lasse Kjær is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (77 papers), Eosinophilic Disorders and Syndromes (36 papers) and Chronic Myeloid Leukemia Treatments (30 papers). Lasse Kjær collaborates with scholars based in Denmark, United States and Germany. Lasse Kjær's co-authors include Hans Carl Hasselbalch, Vibe Skov, O. Henriksen, Christina Ellervik, C. Thomsen, Niels Pallisgaard, Sabrina Cordua, Caroline Hasselbalch Riley, Thomas Stauffer Larsen and Torben A. Kruse and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Lasse Kjær

124 papers receiving 2.0k citations

Peers

Countries citing papers authored by Lasse Kjær

Since Specialization

Citations

This map shows the geographic impact of Lasse Kjær's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lasse Kjær with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lasse Kjær more than expected).

Fields of papers citing papers by Lasse Kjær

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lasse Kjær. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lasse Kjær. The network helps show where Lasse Kjær may publish in the future.

Co-authorship network of co-authors of Lasse Kjær

This figure shows the co-authorship network connecting the top 25 collaborators of Lasse Kjær. A scholar is included among the top collaborators of Lasse Kjær based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lasse Kjær. Lasse Kjær is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The JAK2V617F and CALR mutations and risk of cancer, cardiovascular diseases, and all‐cause mortality 2025 ·Journal of Internal Medicine ·(unknown), Vibe Skov, Lasse Kjær, (unknown), Trine Alma Knudsen, (unknown), Anders Lindholm Sørensen, Sabrina Cordua, Troels Wienecke, (unknown), Morten Andersen, Johnny T. Ottesen, (unknown), (unknown), Henrik E. Poulsen, Thomas Stiehl, Christina Ellervik, Hans Carl Hasselbalch	0
2	Statins enhance the efficacy of pegylated interferon-alfa2 in Philadelphia-negative chronic myeloproliferative neoplasms 2025 ·Blood Advances ·(unknown), (unknown), (unknown), Vibe Skov, Lasse Kjær, Trine Alma Knudsen, Anders Lindholm Sørensen, (unknown), Sabrina Cordua, (unknown), (unknown), Christina Ellervik, Troels Wienecke, Hans Carl Hasselbalch	1
3	JAK2V617F drives gut microbiota differences in patients with myeloproliferative neoplasms 2024 ·European Journal Of Haematology ·(unknown), Henrik Nielsen, Kurt Fuursted, Christen Rune Stensvold, Lee O’Brien Andersen, Berit Lilje, (unknown), Lasse Kjær, (unknown), Trine Alma Knudsen, Vibe Skov, Anders Lindholm Sørensen, Christina Ellervik, Lars Rønn Olsen, Jens Jørgen Christensen, Xiaohui Chen Nielsen, Hans Carl Hasselbalch, Anna Cäcilia Ingham	1
4	The CHIP-clinic as the catalyst of preventive medicine 2024 ·SHILAP Revista de lepidopterología ·Hans Carl Hasselbalch, Vibe Skov, Lasse Kjær, Trine Alma Knudsen, (unknown), Christina Ellervik, Sabrina Cordua, Anders Lindholm Sørensen, (unknown), (unknown), Jes S. Lindholt, Mads Thomassen, Torben A. Kruse, Niels Eske Bruun, Matias Greve Lindholm, Claus Henrik Nielsen, Miklós Egyed, Winfried März, (unknown), Troels Wienecke	1
5	Neutrophil-to-lymphocyte ratio and all-cause mortality with and without myeloproliferative neoplasms—a Danish longitudinal study 2024 ·Blood Cancer Journal ·(unknown), Vibe Skov, Lasse Kjær, (unknown), Trine Alma Knudsen, (unknown), Anders Lindholm Sørensen, Troels Wienecke, Morten Andersen, Johnny T. Ottesen, (unknown), (unknown), Mikkel Porsborg Andersen, Christian Torp‐Pedersen, Henrik E. Poulsen, Thomas Stiehl, Hans Carl Hasselbalch, Christina Ellervik	20
6	Combination therapy with ruxolitinib and pegylated interferon alfa-2a in newly diagnosed patients with polycythemia vera 2024 ·Blood Advances ·Anders Lindholm Sørensen, Vibe Skov, Lasse Kjær, Mads Emil Bjørn, (unknown), (unknown), Claus Henrik Nielsen, Carsten Thomsen, Lise Mette Rahbek Gjerdrum, Trine Alma Knudsen, Christina Ellervik, Ulrik Malthe Overgaard, Christen Lykkegaard Andersen, Hans Carl Hasselbalch	8
7	Proof of concept of triple COMBI therapy to prohibit MPN progression to AML 2023 ·British Journal of Haematology ·Hans Carl Hasselbalch, Vibe Skov, Lasse Kjær, (unknown)	1
8	Therapeutic cancer vaccination against mutant calreticulin in myeloproliferative neoplasms induces expansion of specific T cells in the periphery but specific T cells fail to enrich in the bone marrow 2023 ·Frontiers in Immunology ·Morten Orebo Holmström, Morten Andersen, Sofie Traynor, Shamaila Munir Ahmad, (unknown), (unknown), Vibe Skov, Lasse Kjær, Johnny T. Ottesen, Morten F. Gjerstorff, Hans Carl Hasselbalch, Mads Hald Andersen	5
9	Antibodies to calnexin and mutated calreticulin are common in human sera 2023 ·Current Research in Translational Medicine ·(unknown), Nicole Hartwig Trier, (unknown), Per Brinch Hansen, Morten Orebo Holmström, Daniel El Fassi, Hans Carl Hasselbalch, Vibe Skov, Lasse Kjær, Morten Andersen, Evaldas Čiplys, Rimantas Slibinskas, Jette Lautrup Frederiksen, Peter Højrup, Gunnar Houen	2
10	Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms 2023 ·Cancers ·Hans Carl Hasselbalch, Peter Junker, Vibe Skov, Lasse Kjær, Trine Alma Knudsen, (unknown), Morten Orebo Holmström, Mads Hald Andersen, Christina Jensen, M.A. Karsdal, Nicholas Willumsen	3
11	Lower CXCR3 expression in both patients with neovascular AMD and advanced stages of chronic myeloproliferative blood cancers 2022 ·PLoS ONE ·(unknown), Vibe Skov, Lasse Kjær, Hans Carl Hasselbalch, Torben Lykke Sørensen	3
12	Global dynamics of healthy and cancer cells competing in the hematopoietic system 2020 ·Mathematical Biosciences ·Morten Andersen, Hans Carl Hasselbalch, Lasse Kjær, Vibe Skov, Johnny T. Ottesen	7
13	Smoking, blood cells and myeloproliferative neoplasms: meta‐analysis and Mendelian randomization of 2·3 million people 2019 ·British Journal of Haematology ·(unknown), Alisa D. Kjærgaard, Kasper Mønsted Pedersen, Anders Lindholm Sørensen, Marie Bak, (unknown), Børge G. Nordestgaard, Stig E. Bojesen, Yunus Çolak, Vibe Skov, Lasse Kjær, Janne Schurmann Tolstrup, Hans Carl Hasselbalch, Christina Ellervik	27
14	A 7-Gene Signature Depicts the Biochemical Profile of Early Prefibrotic Myelofibrosis 2016 ·PLoS ONE ·Vibe Skov, Mark Burton, Mads Thomassen, Thomas Stauffer Larsen, Caroline Hasselbalch Riley, (unknown), Lasse Kjær, (unknown), (unknown), Mats Ehinger, (unknown), (unknown), Karsten Nielsen, Jürgen Thiele, Morten K. Jensen, Ole Weis Bjerrum, Torben A. Kruse, Hans Carl Hasselbalch	18
15	Nye sygdomsmarkører ved de kroniske myeloproliferative neoplasier 2015 ·Ugeskrift for Læger ·Morten Orebo Holmström, (unknown), Klaus Kallenbach, Lasse Kjær, Thomas Kielsgaard Kristensen, Niels Pallisgaard, Bodil Laub Petersen, Vibe Skov, Karin de Stricker, Thomas Stauffer Larsen, Hans Carl Hasselbalch	2
16	Supervised multi-classifier separation of the ph-negative myeloproliferative neoplasms 2015 ·Haematologica ·Vibe Skov, Mark Burton, Mads Thomassen, Thomas Stauffer Larsen, Lasse Kjær, Caroline Hasselbalch Riley, Morten K. Jensen, Ole Weis Bjerrum, Torben A. Kruse, Hans Carl Hasselbalch	1
17	The JAK2 V617F somatic mutation, mortality and cancer risk in the general population 2010 ·Haematologica ·(unknown), Henrik Birgens, Børge G. Nordestgaard, Lasse Kjær, Stig E. Bojesen	94
18	Increased brain water content in pseudotumour cerebri measured by magnetic resonance imaging of brain water self diffusion 1989 ·Neurological Research ·Per Soelberg Sørensen, C. Thomsen, F. Gjerris, (unknown), Lasse Kjær, O. Henriksen	32
19	SPECT in partial epilepsy: Identifying side of the focus 1988 ·Acta Neurologica Scandinavica ·Andreas Andersen, L. F. Gram, Lasse Kjær, Anders Fuglsang‐Frederiksen, Margrethe Herning, Niels A. Lassen, M. Dam	13
20	Radionuclide Scanning After Total Knee Replacement: Correlation with Pain and Radiolucent Lines A Prospective Study 1987 ·Investigative Radiology ·Benn Duus, Michel E. H. Boeckstyns, Lasse Kjær, C. Stadeager	23

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact